120 related articles for article (PubMed ID: 2480798)
21. In vivo effect of a new mineral condensed ion (HPA 39) on murine Friend leukaemia.
Larnicol N; Augery Y; Le Bousse-Kerdiles C; Degiorgis V; Chermann JC; Teze A; Jasmin C
J Gen Virol; 1981 Jul; 55(Pt 1):17-23. PubMed ID: 7299368
[TBL] [Abstract][Full Text] [Related]
22. Quantitation of human immunodeficiency virus in vertically infected infants and children.
Alimenti A; Luzuriaga K; Stechenberg B; Sullivan JL
J Pediatr; 1991 Aug; 119(2):225-9. PubMed ID: 1677684
[TBL] [Abstract][Full Text] [Related]
23. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.
Schwartz DH; Skowron G; Merigan TC
J Acquir Immune Defic Syndr (1988); 1991; 4(1):11-23. PubMed ID: 1670586
[TBL] [Abstract][Full Text] [Related]
24. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group.
Roberts RB; Hollinger FB; Parks WP; Rasheed S; Laurence J; Heseltine PN; Makuch RW; Lubina JA; Johnson KM
AIDS; 1990 Jan; 4(1):67-72. PubMed ID: 1690551
[TBL] [Abstract][Full Text] [Related]
25. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
Saag MS; Crain MJ; Decker WD; Campbell-Hill S; Robinson S; Brown WE; Leuther M; Whitley RJ; Hahn BH; Shaw GM
J Infect Dis; 1991 Jul; 164(1):72-80. PubMed ID: 1676046
[TBL] [Abstract][Full Text] [Related]
26. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
[TBL] [Abstract][Full Text] [Related]
27. Sensitive one-step enzyme immunoassay for HIV-1 p24 antigen in human blood specimens and cell culture supernatants.
Kontio S
J Immunol Methods; 1991 Jun; 139(2):257-63. PubMed ID: 1904466
[TBL] [Abstract][Full Text] [Related]
28. Suppressive effect of polyoxometalates on the cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) in vitro and their inhibitory activity against HIV-1 reverse transcriptase.
Inouye Y; Tokutake Y; Kunihara J; Yoshida T; Yamase T; Nakata A; Nakamura S
Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):805-7. PubMed ID: 1377101
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine.
Berglund O; Engman K; Ehrnst A; Andersson J; Lidman K; Akerlund B; Sönnerborg A; Strannegård O
J Infect Dis; 1991 Apr; 163(4):710-5. PubMed ID: 1672701
[TBL] [Abstract][Full Text] [Related]
30. Human immunodeficiency virus type 1 (HIV-1) genomic sequences and distinct changes in CD8+ lymphocytes precede detectable levels of HIV-1 antibodies in high-risk homosexuals.
Yagi MJ; Joesten ME; Wallace J; Roboz JP; Bekesi JG
J Infect Dis; 1991 Jul; 164(1):183-8. PubMed ID: 1829106
[TBL] [Abstract][Full Text] [Related]
31. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
[TBL] [Abstract][Full Text] [Related]
32. Effects of suramin, HPA-23 and 3'-azidothymidine triphosphate on the reverse transcriptase of bovine leukaemia virus.
Reimer K; Matthes E; Scholz D; Rosenthal HA
Acta Virol; 1989 Jan; 33(1):43-9. PubMed ID: 2469327
[TBL] [Abstract][Full Text] [Related]
33. Reverse transcriptase activity (RTA) in lymphocyte cultures of AIDS patients treated with HPA-23.
Buimovici-Klein E; Ong KR; Lange M; Englard A; McKinley GF; Reddy M; Grieco MH; Cooper LZ
AIDS Res; 1986; 2(4):279-83. PubMed ID: 2434115
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome.
Moskovitz BL
Antimicrob Agents Chemother; 1988 Sep; 32(9):1300-3. PubMed ID: 3058016
[TBL] [Abstract][Full Text] [Related]
35. Surrogate markers for AIDS treatment.
Jacobson M
Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
[No Abstract] [Full Text] [Related]
36. Prospects of therapy for infections with human T-lymphotropic virus type III.
Hirsch MS; Kaplan JC
Ann Intern Med; 1985 Nov; 103(5):750-5. PubMed ID: 2413793
[TBL] [Abstract][Full Text] [Related]
37. Cellular and molecular mechanisms of antiretroviral effects of HPA23.
Dormont D; Yeramian P; Lambert P; Spire B; Daveloose D; Barre-Sinoussi FC; Chermann JC
Cancer Detect Prev; 1988; 12(1-6):181-94. PubMed ID: 2460236
[TBL] [Abstract][Full Text] [Related]
38. Lack of transmission of HIV to sexual and non-sexual contacts to HIV seropositive haemophiliacs following preventive information.
Berntorp E; Christensen P; Lindvall K
Scand J Infect Dis; 1990; 22(3):279-82. PubMed ID: 2115204
[TBL] [Abstract][Full Text] [Related]
39. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.
Luzuriaga K; Koup RA; Pikora CA; Brettler DB; Sullivan JL
J Pediatr; 1991 Aug; 119(2):230-6. PubMed ID: 1907319
[TBL] [Abstract][Full Text] [Related]
40. Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia.
MacDonell KB; Chmiel JS; Poggensee L; Wu S; Phair JP
Am J Med; 1990 Dec; 89(6):706-12. PubMed ID: 1979205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
